Cover Image
Market Research Report

Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H1 2020

Published by Global Markets Direct Product code 232797
Published Content info 639 Pages
Delivery time: 1-2 business days
Price
Back to Top
Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H1 2020
Published: February 28, 2020 Content info: 639 Pages
Description

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Pipeline Review, H1 2020, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 50, 24, 4, 54, 23 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 8 and 2 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11983IDB

Table of Contents

Introduction

  • Atopic Dermatitis (Atopic Eczema) - Overview
  • Atopic Dermatitis (Atopic Eczema) - Therapeutics Development
  • Atopic Dermatitis (Atopic Eczema) - Therapeutics Assessment
  • Atopic Dermatitis (Atopic Eczema) - Companies Involved in Therapeutics Development
  • Atopic Dermatitis (Atopic Eczema) - Drug Profiles
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects
  • Atopic Dermatitis (Atopic Eczema) - Discontinued Products
  • Atopic Dermatitis (Atopic Eczema) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..7), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..8), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..9), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..10), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by 3SBio Inc, H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Abate Med Inc, H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by AbbVie Inc, H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Abeome Corp, H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..4), H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..5), H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..6), H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..7), H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..8), H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..9), H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Discontinued Products, H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Discontinued Products, H1 2020 (Contd..1), H1 2020

List of Figures

  • Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Back to Top